Walvax Biotechnology Co., Ltd. (SHE:300142)
China
· Delayed Price · Currency is CNY 11.71
+0.04 (0.34%)
At close: Dec 5, 2025
Walvax Biotechnology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 2,381 | 2,804 | 4,106 | 5,079 | 3,452 | 2,927 | Upgrade
|
| Other Revenue | 17.86 | 17.86 | 7.92 | 7.65 | 10.5 | 11.62 | Upgrade
|
| Revenue | 2,399 | 2,821 | 4,114 | 5,086 | 3,463 | 2,939 | Upgrade
|
| Revenue Growth (YoY) | -22.54% | -31.41% | -19.12% | 46.89% | 17.82% | 162.13% | Upgrade
|
| Cost of Revenue | 786.39 | 740.48 | 749.39 | 673.14 | 403.54 | 404.53 | Upgrade
|
| Gross Profit | 1,613 | 2,081 | 3,364 | 4,413 | 3,059 | 2,534 | Upgrade
|
| Selling, General & Admin | 1,334 | 1,400 | 1,817 | 2,302 | 1,636 | 1,352 | Upgrade
|
| Research & Development | 381.14 | 596.54 | 776.43 | 922.25 | 616.36 | 173.78 | Upgrade
|
| Other Operating Expenses | 25.2 | -4.12 | -100 | 16.48 | 19.83 | -8.34 | Upgrade
|
| Operating Expenses | 1,931 | 2,057 | 2,533 | 3,239 | 2,267 | 1,511 | Upgrade
|
| Operating Income | -317.99 | 24.01 | 831.05 | 1,174 | 792.22 | 1,024 | Upgrade
|
| Interest Expense | -0.75 | -8.43 | -5.95 | -7.11 | -5.77 | -0.6 | Upgrade
|
| Interest & Investment Income | 77.33 | 66.75 | 81.35 | 81.82 | 103.29 | 42.83 | Upgrade
|
| Currency Exchange Gain (Loss) | 4.05 | 4.05 | 3.06 | 0.82 | -0.22 | -4.65 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.58 | 80.95 | -63.64 | -75.39 | 33.88 | 39.57 | Upgrade
|
| EBT Excluding Unusual Items | -236.78 | 167.33 | 845.86 | 1,174 | 923.4 | 1,101 | Upgrade
|
| Gain (Loss) on Sale of Investments | 87.15 | -98.34 | -234.75 | -199.33 | -280.74 | 279.89 | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.48 | -1.77 | -0.83 | -0.38 | 0.23 | -1.08 | Upgrade
|
| Asset Writedown | -31.85 | -7.68 | -11.31 | -1.66 | -5.11 | -6.6 | Upgrade
|
| Other Unusual Items | 129.95 | 124.96 | - | 97.8 | 71.15 | - | Upgrade
|
| Pretax Income | -53.01 | 184.5 | 598.98 | 1,070 | 708.95 | 1,373 | Upgrade
|
| Income Tax Expense | 19.72 | 10.1 | 87.65 | 132.24 | 107.59 | 162.12 | Upgrade
|
| Earnings From Continuing Operations | -72.73 | 174.4 | 511.33 | 938.23 | 601.35 | 1,211 | Upgrade
|
| Net Income to Company | -72.73 | 174.4 | 511.33 | 938.23 | 601.35 | 1,211 | Upgrade
|
| Minority Interest in Earnings | 121.97 | -32.24 | -91.93 | -209.57 | -173.6 | -208 | Upgrade
|
| Net Income | 49.24 | 142.16 | 419.39 | 728.65 | 427.75 | 1,003 | Upgrade
|
| Net Income to Common | 49.24 | 142.16 | 419.39 | 728.65 | 427.75 | 1,003 | Upgrade
|
| Net Income Growth | -59.76% | -66.10% | -42.44% | 70.35% | -57.36% | 606.60% | Upgrade
|
| Shares Outstanding (Basic) | 1,599 | 1,599 | 1,600 | 1,603 | 1,569 | 1,539 | Upgrade
|
| Shares Outstanding (Diluted) | 1,599 | 1,599 | 1,600 | 1,604 | 1,573 | 1,559 | Upgrade
|
| Shares Change (YoY) | -0.01% | -0.06% | -0.21% | 1.93% | 0.90% | 1.37% | Upgrade
|
| EPS (Basic) | 0.03 | 0.09 | 0.26 | 0.45 | 0.27 | 0.65 | Upgrade
|
| EPS (Diluted) | 0.03 | 0.09 | 0.26 | 0.45 | 0.27 | 0.64 | Upgrade
|
| EPS Growth | -59.75% | -66.08% | -42.32% | 67.12% | -57.74% | 597.07% | Upgrade
|
| Free Cash Flow | 94.83 | 486.49 | 188.25 | 110.31 | -398.21 | -292.94 | Upgrade
|
| Free Cash Flow Per Share | 0.06 | 0.30 | 0.12 | 0.07 | -0.25 | -0.19 | Upgrade
|
| Dividend Per Share | 0.010 | 0.010 | 0.010 | 0.010 | 0.027 | 0.070 | Upgrade
|
| Dividend Growth | - | - | - | -62.96% | -61.43% | - | Upgrade
|
| Gross Margin | 67.22% | 73.76% | 81.78% | 86.77% | 88.35% | 86.24% | Upgrade
|
| Operating Margin | -13.26% | 0.85% | 20.20% | 23.08% | 22.88% | 34.84% | Upgrade
|
| Profit Margin | 2.05% | 5.04% | 10.20% | 14.32% | 12.35% | 34.13% | Upgrade
|
| Free Cash Flow Margin | 3.95% | 17.24% | 4.58% | 2.17% | -11.50% | -9.97% | Upgrade
|
| EBITDA | 100.82 | 387.61 | 1,121 | 1,422 | 927.65 | 1,148 | Upgrade
|
| EBITDA Margin | 4.20% | 13.74% | 27.25% | 27.96% | 26.79% | 39.06% | Upgrade
|
| D&A For EBITDA | 418.81 | 363.59 | 289.97 | 248.4 | 135.43 | 123.95 | Upgrade
|
| EBIT | -317.99 | 24.01 | 831.05 | 1,174 | 792.22 | 1,024 | Upgrade
|
| EBIT Margin | -13.26% | 0.85% | 20.20% | 23.08% | 22.88% | 34.84% | Upgrade
|
| Effective Tax Rate | - | 5.48% | 14.63% | 12.35% | 15.18% | 11.80% | Upgrade
|
| Revenue as Reported | 2,399 | 2,821 | 4,114 | 5,086 | - | - | Upgrade
|
| Advertising Expenses | - | 42.66 | 78.01 | 94.83 | 24.15 | 20.85 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.